212 related articles for article (PubMed ID: 23144194)
21. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
22. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
23. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.
Efremov DG; Gobessi S; Longo PG
Autoimmun Rev; 2007 Dec; 7(2):102-8. PubMed ID: 18035318
[TBL] [Abstract][Full Text] [Related]
24. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.
Rozovski U; Harris DM; Li P; Liu Z; Jain P; Veletic I; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
Int J Cancer; 2017 Nov; 141(10):2076-2081. PubMed ID: 28722170
[TBL] [Abstract][Full Text] [Related]
25. Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.
Palazzo AL; Evensen E; Huang YW; Cesano A; Nolan GP; Fantl WJ
PLoS One; 2011; 6(10):e24592. PubMed ID: 22016760
[TBL] [Abstract][Full Text] [Related]
26. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
27. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
28. The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia.
Grzywnowicz M; Karabon L; Karczmarczyk A; Zajac M; Skorka K; Zaleska J; Wlasiuk P; Chocholska S; Tomczak W; Bojarska-Junak A; Dmoszynska A; Frydecka I; Giannopoulos K
Leuk Lymphoma; 2015; 56(10):2908-13. PubMed ID: 25682964
[TBL] [Abstract][Full Text] [Related]
29. Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL.
Kaplan D; Meyerson HJ; Li X; Drasny C; Liu F; Costaldi M; Barr P; Lazarus HM
Cytometry B Clin Cytom; 2010 Mar; 78(2):115-22. PubMed ID: 20014315
[TBL] [Abstract][Full Text] [Related]
30. Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia.
Johansson P; Eisele L; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J; Nückel H
Leuk Res; 2010 Jul; 34(7):892-8. PubMed ID: 20353875
[TBL] [Abstract][Full Text] [Related]
31. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
[TBL] [Abstract][Full Text] [Related]
32. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
33. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
Rozovski U; Wu JY; Harris DM; Liu Z; Li P; Hazan-Halevy I; Ferrajoli A; Burger JA; O'Brien S; Jain N; Verstovsek S; Wierda WG; Keating MJ; Estrov Z
Blood; 2014 Jun; 123(24):3797-802. PubMed ID: 24778152
[TBL] [Abstract][Full Text] [Related]
34. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.
Mansouri L; Sutton LA; Ljungström V; Bondza S; Arngården L; Bhoi S; Larsson J; Cortese D; Kalushkova A; Plevova K; Young E; Gunnarsson R; Falk-Sörqvist E; Lönn P; Muggen AF; Yan XJ; Sander B; Enblad G; Smedby KE; Juliusson G; Belessi C; Rung J; Chiorazzi N; Strefford JC; Langerak AW; Pospisilova S; Davi F; Hellström M; Jernberg-Wiklund H; Ghia P; Söderberg O; Stamatopoulos K; Nilsson M; Rosenquist R
J Exp Med; 2015 Jun; 212(6):833-43. PubMed ID: 25987724
[TBL] [Abstract][Full Text] [Related]
35. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation.
Heinig K; Gätjen M; Grau M; Stache V; Anagnostopoulos I; Gerlach K; Niesner RA; Cseresnyes Z; Hauser AE; Lenz P; Hehlgans T; Brink R; Westermann J; Dörken B; Lipp M; Lenz G; Rehm A; Höpken UE
Cancer Discov; 2014 Dec; 4(12):1448-65. PubMed ID: 25252690
[TBL] [Abstract][Full Text] [Related]
36. Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia.
Ziegler CGK; Kim J; Piersanti K; Oyler-Yaniv A; Argyropoulos KV; van den Brink MRM; Palomba ML; Altan-Bonnet N; Altan-Bonnet G
Cell Rep; 2019 Jul; 28(4):923-937.e3. PubMed ID: 31340154
[TBL] [Abstract][Full Text] [Related]
37. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.
Perbellini O; Falisi E; Giaretta I; Boscaro E; Novella E; Facco M; Fortuna S; Finotto S; Amati E; Maniscalco F; Montaldi A; Alghisi A; Aprili F; Bonaldi L; Paolini R; Scupoli MT; Trentin L; Ambrosetti A; Semenzato G; Pizzolo G; Rodeghiero F; Visco C
Haematologica; 2014 May; 99(5):881-7. PubMed ID: 24415628
[TBL] [Abstract][Full Text] [Related]
39. Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells.
Cutrona G; Colombo M; Matis S; Fabbi M; Spriano M; Callea V; Vigna E; Gentile M; Zupo S; Chiorazzi N; Morabito F; Ferrarini M
Haematologica; 2008 Mar; 93(3):413-22. PubMed ID: 18287138
[TBL] [Abstract][Full Text] [Related]
40. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
